NCT05683015View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Psoriasis Vulgaris
Interventions
PROCEDURE

Venapuncture

Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of tildrakizumab.

PROCEDURE

Patient questionnaires

The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.

Trial Locations (2)

9000

RECRUITING

University Hospital Ghent, Ghent

RECRUITING

University Hospital Ghent, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER